IRINOTECAN AND TEMOZOLAMIDE AS EFFECTIVE SCHEDULE IN PROGRESSIVE AND THERAPY RESISTANT NEUROBLASTOMA - EXPERIENCE OF POLISH PEDIATRIC SOLID TUMORS GROUP

被引：0
|
作者：
Wieczorek, A. [1 ]
Stypinska, M. [2 ]
Hennig, M. [3 ]
Wieczorek, M. [4 ]
Januszkiewicz-Lewandowska, D. [5 ]
Zubowska, M. [6 ]
Peszynska-Bialczynska, K. [7 ]
Sobol-Milewska, G. [8 ]
Ussowicz, M. [9 ]
Balwierz, W. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Polish Amer Inst Pediat, Krakow, Poland
[2] Childrens Mem Hlth Inst, Warsaw, Poland
[3] Med Univ Gdansk, Gdansk, Poland
[4] Chorzow Ctr Pediat & Oncol, Chorzow, Poland
[5] Med Univ, Poznan, Poland
[6] Med Univ, Lodz, Poland
[7] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Bydgoszcz, Poland
[8] Med Univ Silesia, Upper Silesia Childrens Care Hlth Ctr, Katowice, Poland
[9] Med Univ, Wroclaw, Poland
来源：
PEDIATRIC BLOOD & CANCER | 2014年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-374
引用
收藏
页码：S337 / S337
页数：1
相关论文
共 26 条
  • [21] Remaining problems and controversies in the management of childhood head and neck soft tissue sarcomas: Retrospective (national) multicenter study of the Polish Pediatric Solid Tumors Group
    Kazanowska, B
    Reich, A
    Reich, M
    Balcerska, A
    Balwierz, W
    Bodalski, J
    Dluzniewska, A
    Drozynska, E
    Katski, K
    Kijowski, J
    Kowalczyk, J
    Kurylak, A
    Matysiak, M
    Mikolajewska, A
    Peregut-Pogorzelski, J
    Sopylo, B
    Stencel, D
    Szewczyk, B
    Wachowiak, J
    Wieczorek, M
    Wysocki, M
    Chybicka, A
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2004, 21 (04) : 349 - 362
  • [22] Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors
    Krishna, R
    Mayer, LD
    CANCER RESEARCH, 1997, 57 (23) : 5246 - 5253
  • [23] ADOPTIVE THERAPY WITH DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - EXPERIENCE OF THE POLISH PEDIATRIC GROUP FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (PPGHSCT)
    Gozdzik, J.
    Rewucka-siewiera, K.
    Krasowska-Kwiecien, A.
    Pieczonka, A.
    Debski, R.
    Zaucha-Prazmo, A.
    Drabko, K.
    Kowalczyk, J.
    Wysocki, M.
    Gorczynska, E.
    Kalwak, K.
    Chybicka, A.
    Wachowiak, J.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S159 - S160
  • [24] TOXICITY OF HIGH-DOSE CYTOSINE-ARABINOSIDE IN THE TREATMENT OF ADVANCED CHILDHOOD TUMORS RESISTANT TO CONVENTIONAL THERAPY - A PEDIATRIC ONCOLOGY GROUP-STUDY
    TEBBI, CK
    KRISCHER, J
    FERNBACH, DJ
    MAHONEY, DH
    ALVARADO, C
    CAMITTA, B
    CANCER, 1990, 66 (10) : 2064 - 2067
  • [25] A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514
    Cramer, Stuart L.
    Reddy, Alyssa Terry
    Minard, Charles Gene
    Voss, Stephan
    Fox, Elizabeth
    Liu, Xiaowei
    Denic, Kristina
    Reid, Joel M.
    Weigel, Brenda J.
    CANCER MEDICINE, 2024, 13 (21):
  • [26] ADVL1514, a phase 1 study of ABI-009 (nab-sirolimus) in pediatric patients with recurrent or refractory solid tumors, including CNS tumors as a single agent and in combination with temozolomide and irinotecan: A Children's Oncology Group pediatric early-phase clinical trial network study.
    Cramer, Stuart
    Gilger, Elizabeth Ann
    Burlingame, Susan
    Militano, Olga
    Liu, Xiaowei
    Minard, Charles G.
    Reddy, Alyssa Terry
    Voss, Stephan D.
    Berg, Stacey L.
    Reid, Joel M.
    Fox, Elizabeth
    Weigel, Brenda
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
123